Amaroq Therapeutics is a biotech firm developing cancer therapies targeting long non-coding RNAs.
Amaroq Therapeutics has raised $9.7M in total funding. The most recent round was Seed. The last funding was announced in July 2021.
Amaroq Therapeutics's investors include Brandon Capital, Booster, Otago Innovation, Cure Kids Ventures.
Amaroq Therapeutics is headquartered in Auckland, New Zealand.
Amaroq Therapeutics is a biotech firm developing cancer therapies targeting long non-coding RNAs.
Amaroq Therapeutics is at the Seed stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Amaroq Therapeutics — Funding & Investors." VCBacked, July 8, 2021, https://www.vcbacked.co/company/amaroq-therapeutics. Accessed September 30, 2026.
VCBacked. (2021). Amaroq Therapeutics — Funding & Investors. Retrieved September 30, 2026, from https://www.vcbacked.co/company/amaroq-therapeutics
{{cite web |title=Amaroq Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/amaroq-therapeutics |website=VCBacked |access-date=September 30, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated